美迪西: 美迪西：第四届监事会第六次会议决议公告

Core Viewpoint - The Shanghai Medicy Biopharmaceutical Co., Ltd. held its sixth meeting of the fourth Supervisory Board, where several key resolutions were passed regarding the company's 2025 semi-annual report, fundraising management, and stock incentive plans [1][2][3][4][5][6][7][8]. Meeting Details - The meeting was convened on August 27, 2025, with all three supervisors present, confirming compliance with relevant laws and regulations [1]. - The meeting's resolutions were passed unanimously with 3 votes in favor, 0 against, and 0 abstentions [2][3][4][5][6][7][8]. Resolutions Passed - Approval of the 2025 semi-annual report and its summary, confirming adherence to legal and regulatory requirements [1][2]. - Approval of a special report on the management and actual use of raised funds for the first half of 2025 [2][3]. - Approval to increase the expected daily related transactions for 2025, ensuring no harm to the company or shareholders [3][4]. - Approval to terminate certain fundraising projects and redirect remaining funds to new projects and working capital, with no adverse impact on operations [4][5]. - Approval to cancel the Supervisory Board and amend the company’s articles of association, pending shareholder meeting approval [5][6]. - Approval of the 2025 restricted stock incentive plan draft, which aligns with legal requirements and supports the company's sustainable development [5][6][7]. - Approval of the assessment management measures for the implementation of the restricted stock incentive plan [6][7]. - Approval of the verification of the initial grant list for the restricted stock incentive plan, ensuring compliance with relevant regulations [7][8].